BR0317146A - Derivado de hemissulfato de azido citosina cristalino anidro - Google Patents

Derivado de hemissulfato de azido citosina cristalino anidro

Info

Publication number
BR0317146A
BR0317146A BR0317146-9A BR0317146A BR0317146A BR 0317146 A BR0317146 A BR 0317146A BR 0317146 A BR0317146 A BR 0317146A BR 0317146 A BR0317146 A BR 0317146A
Authority
BR
Brazil
Prior art keywords
cytosine
azide
anhydrous crystalline
derivative
hemisulfate
Prior art date
Application number
BR0317146-9A
Other languages
English (en)
Inventor
Terrence Joseph Connolly
Joseph Armstrong Martin
Anthony Prince
Keshab Sarma
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0317146A publication Critical patent/BR0317146A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"DERIVADO DE HEMISSULFATO DE AZIDO CITOSINA CRISTALINO ANIDRO". A presente invenção refere-se ao sal de hemissulfato de 1-¢4(S)azido-2(S),3(R)-dihidróxi-4-(hidroximetil)-1(R)-ciclopentil!citosin a (Ia) com melhores estabilidade e propriedades físicas que facilitam a fabricação, manuseio e formulação de (1) e suas formas cristalinas polimórficas.
BR0317146-9A 2002-12-09 2003-12-08 Derivado de hemissulfato de azido citosina cristalino anidro BR0317146A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43188502P 2002-12-09 2002-12-09
PCT/EP2003/013899 WO2004052906A1 (en) 2002-12-09 2003-12-08 Anhydrous crystalline azido cytosine hemisulfate derivative

Publications (1)

Publication Number Publication Date
BR0317146A true BR0317146A (pt) 2005-10-25

Family

ID=32507815

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317146-9A BR0317146A (pt) 2002-12-09 2003-12-08 Derivado de hemissulfato de azido citosina cristalino anidro

Country Status (33)

Country Link
US (1) US6864244B2 (pt)
EP (1) EP1572711B1 (pt)
JP (1) JP4563818B2 (pt)
KR (1) KR100675544B1 (pt)
CN (1) CN1314697C (pt)
AR (1) AR042312A1 (pt)
AT (1) ATE430755T1 (pt)
AU (1) AU2003292212B2 (pt)
BR (1) BR0317146A (pt)
CA (1) CA2506532C (pt)
CY (1) CY1109296T1 (pt)
DE (1) DE60327554D1 (pt)
DK (1) DK1572711T3 (pt)
ES (1) ES2324654T3 (pt)
GT (1) GT200300276A (pt)
HK (1) HK1085483A1 (pt)
HR (1) HRP20050503A2 (pt)
IL (1) IL168685A (pt)
JO (1) JO2542B1 (pt)
MX (1) MXPA05006044A (pt)
MY (1) MY130927A (pt)
NO (1) NO330454B1 (pt)
NZ (1) NZ540297A (pt)
PA (1) PA8590701A1 (pt)
PE (1) PE20040767A1 (pt)
PL (1) PL213734B1 (pt)
PT (1) PT1572711E (pt)
RU (1) RU2334756C2 (pt)
SI (1) SI1572711T1 (pt)
TW (1) TWI294882B (pt)
UY (1) UY28109A1 (pt)
WO (1) WO2004052906A1 (pt)
ZA (1) ZA200504472B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1219607B1 (en) * 1999-09-02 2011-04-06 Shionogi & Co., Ltd. Integrase inhibitors containing aromatic heterocycle derivatives
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
DE602005015466D1 (de) * 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
ES2392948T3 (es) * 2006-10-10 2012-12-17 Janssen Products, L.P. Intermedio para inhibidores nucleosídicos de VHC
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
ES2701020T3 (es) 2010-09-22 2019-02-20 Alios Biopharma Inc Nucleósidos azido y análogos nucleotídicos
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN103965116B (zh) * 2014-05-06 2016-06-15 中国科学院苏州纳米技术与纳米仿生研究所 半5-氟胞嘧啶盐、其制备方法及应用
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
GEP20247600B (en) 2015-03-06 2024-02-26 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN115536710B (zh) * 2022-10-18 2024-04-16 南京工业大学 一种高品质胞苷硫酸盐晶体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449664A (en) * 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
FI895514A0 (fi) * 1988-11-21 1989-11-20 Syntex Inc Antivirala aemne.
AU7623991A (en) * 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives

Also Published As

Publication number Publication date
US6864244B2 (en) 2005-03-08
HK1085483A1 (en) 2006-08-25
EP1572711B1 (en) 2009-05-06
AU2003292212A1 (en) 2004-06-30
MY130927A (en) 2007-07-31
JO2542B1 (en) 2010-09-05
MXPA05006044A (es) 2005-08-18
SI1572711T1 (sl) 2009-08-31
NZ540297A (en) 2007-05-31
KR20050084217A (ko) 2005-08-26
NO20052732D0 (no) 2005-06-07
PE20040767A1 (es) 2004-11-06
GT200300276A (es) 2004-09-02
ZA200504472B (en) 2006-02-22
JP2006510649A (ja) 2006-03-30
US20040162265A1 (en) 2004-08-19
RU2334756C2 (ru) 2008-09-27
ATE430755T1 (de) 2009-05-15
ES2324654T3 (es) 2009-08-12
WO2004052906A1 (en) 2004-06-24
PT1572711E (pt) 2009-06-25
AU2003292212B2 (en) 2009-10-01
RU2005121927A (ru) 2006-01-27
UY28109A1 (es) 2004-06-30
CA2506532A1 (en) 2004-06-24
CA2506532C (en) 2011-09-20
NO330454B1 (no) 2011-04-18
DK1572711T3 (da) 2009-07-13
HRP20050503A2 (en) 2006-12-31
PL213734B1 (pl) 2013-04-30
DE60327554D1 (de) 2009-06-18
CN1314697C (zh) 2007-05-09
TW200502243A (en) 2005-01-16
EP1572711A1 (en) 2005-09-14
CN1723215A (zh) 2006-01-18
NO20052732L (no) 2005-09-06
CY1109296T1 (el) 2014-07-02
PA8590701A1 (es) 2004-11-26
PL377472A1 (pl) 2006-02-06
IL168685A (en) 2010-11-30
AR042312A1 (es) 2005-06-15
TWI294882B (en) 2008-03-21
KR100675544B1 (ko) 2007-01-30
JP4563818B2 (ja) 2010-10-13

Similar Documents

Publication Publication Date Title
BR0317146A (pt) Derivado de hemissulfato de azido citosina cristalino anidro
ES2500515T3 (es) Síntesis y utilización de análogos de fosforotioato antiinversos de la caperuza de ARN mensajero
WO2006015357A3 (en) 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
PE20050330A1 (es) Compuestos de indazol 3,5-disustituidos como inhibidores de cinasa dependiente de ciclina (cdk)
BR0309933A (pt) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetraidrofurilc arbonil)-4-piperidinil-metil]-4-piperidinil] benzamida, processo para sua preparação, composição farmacêutica contendo o mesmo e intermediários obtidos desta forma
BR0207209A (pt) Inibidores de metaloproteinase de matriz de pirimidina
HUP0001843A2 (hu) Eljárás nukleozid analógok szintézisére
BR0316056A (pt) Processo para a preparação de compostos de pirrolotriazina úteis como inibidores de cinase
CR9730A (es) Mezclas fungicidas que contienen anilidas sustituidas de acido 1-metilpirazol-4-ilcarboxilico
MA27040A1 (fr) Nucleosides substitues en 4'
DOP2002000337A (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas
FI93831B (fi) Tetratsolit, jotka ovat verenpainetta alentavien yhdisteiden välituotteita
GT200300038A (es) Nuevos derivados de piridina y quinolina
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
MXPA02011370A (es) Iminoazinas substituidas.
CY1108808T1 (el) Ενωσεις μοτιλιδης
BR0307327A (pt) Material de embrulhar com um sistema de fecho em z e métodos para fabricar e utilizar o mesmo
BRPI0412558A (pt) processo para a preparação de derivados de tetrazol de azidas de organoboro e organoalumìnio
DE60031886D1 (de) Purinderivate
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
HN1998000071A (es) Una nueva sal
BR0112598A (pt) Processo para a preparação de (r,s)-axetil cefuroxima cristalina de alta pureza
DK1217898T3 (da) Hårde karameller med forbedret lagerstabilitet
BR0312183A (pt) Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica
TW200420574A (en) Avermectin-and avermectin monosaccharide derivatives substituted in the 4"-or 4'-position having pesticidal properties

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.